Static Chart Nektar Therapeutics

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
1.64 ^USD	+9.33%		-0.61%	+190.27%

Apr. 24	Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	CI
Mar. 19	Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	CI

Duration

Period